Close Menu

NEW YORK (GenomeWeb) – For metastatic melanoma, BRAF genotyping is typically performed to determine the best pharmacotherapy, but different genotyping methods can have differing efficiencies and ideal uses, particularly in the case of formalin-fixed, paraffin-embedded samples.

According to a new head-to-head comparison of five BRAF genotyping methods performed at the University of Lorraine and Lorraine Cancer Institute in France, certain PCR-based tests are more suitable than others while immunohistochemistry should only be used as a screening tool.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.